Concomitant Prostate Needle Biopsy and Laser Vaporization of the Prostate Could Be a Risk of Postoperative Hemoglobin Decline, a Retrospective Study.

PURPOSE

Contact laser vaporization of the prostate (CVP) for benign prostatic hyperplasia is a widely accepted and safe procedure for elderly patients because of its lower bleeding risks. However, CVP lacks a postoperative pathological examination for prostate cancer. Concomitant prostate biopsy and CVP may complement this disadvantage; however, the risk of bleeding associated with this procedure remains unclear. This study aimed to evaluate the safety of a concomitant prostate biopsy and CVP.

PATIENTS AND METHODS

This retrospective study included 106 men who had undergone CVP in Nerima General Hospital. Prostate biopsies and CVP were performed simultaneously on 16 patients. We defined the "hemorrhage group" by a >5% decrease in hemoglobin the day after surgery. Preoperative and operative indices were evaluated based on the association with the hemorrhage group.

RESULTS

Participants in the concomitant biopsy group were older ( = 0.001), had larger prostates ( = 0.014), a lower rate of prostate biopsy history ( = 0.046), longer postoperative urinary catheter duration ( = 0.024), and a higher rate of decline in hemoglobin levels the day after surgery ( = 0.023). Patients in the hemorrhage group ( = 20, 18.9%) showed a significantly higher rate of concomitant biopsy and CVP ( = 0.006). Multivariate analysis showed that concomitant prostate biopsy ( = 0.009, odds ratio = 4.61) was the sole statistically significant predictive factor for hemorrhage.

CONCLUSION

Concomitant prostate biopsy and CVP of the prostate may increase the risk of bleeding.